Rasilez, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older
Links shared publicly online about this topic.
- 2,485total visits
Rasilez, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older
Basel, November 11, 2008 - New clinical data presented today show first-in-class direct renin inhibitor Rasilez [*] (aliskiren), known as Tekturna in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1].
View full resource at novartis.com
Tags: Heart Disease, Post Heart Attack Medication, Heart Failure Medication, High Blood Pressure, High Blood Pressure Medication, Delix, Tritace, Altace
Most Recently Shared on November 11, 2008 at 6:19 pm By:
Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than .. http://tinyurl.com/66erzc
Advertisement
